Molecule News and Research

RSS

Third quarter 2009 financial results announced by Synta Pharmaceuticals

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended September 30, 2009.

4 Nov 2009

Exelixis to present 13 abstracts of its development candidates at the 2009 AACR-NCI-EORTC Conference

Exelixis, Inc. announced today that thirteen abstracts related to the company’s development candidates have been accepted for presentation at the 2009 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is being held November 15-19 in Boston. Interim data from ongoing phase 1 clinical trials of XL147 and XL765 will be reported in four poster presentations.

4 Nov 2009

Researchers to find better ways to manage chronic pain by treating neuroinflammation

Thanks to a two year, $974,024 NIH-funded ARRA (American Recovery and Reinvestment Act) grant, Saint Louis University and Southern Illinois University Edwardsville researchers are working to find better ways to manage chronic pain by treating neuroinflammation.

4 Nov 2009

Hydrogen peroxide may act as a signal for the active and resting phases of living things: Study

If a circadian rhythm is like an orchestra - the united expression of the rhythms of millions of cells - a common chemical may serve as the conductor, or at least as the baton.

4 Nov 2009

Scientists identify compounds that hold promise for treating parasitic infection

Using an unconventional approach that they designed, University of Pittsburgh drug discoverers and their collaborators at Walter Reed Army Institute of Research have identified compounds that hold promise for treating leishmaniasis, a parasitic infection that many consider one of the world's most overlooked diseases.

4 Nov 2009

New molecular pathway for preventing potassium from being excreted normally through kidney identified

Researchers at the University of Maryland School of Medicine have made an important discovery about why potassium builds up to dangerous levels in the bloodstream, a relatively common medical problem that affects about eight percent of hospitalized patients.

4 Nov 2009

Lovastatin-synthesizing enzyme successfully reconstituted

Researchers from the UCLA Henry Samueli School of Engineering and Applied Science have for the first time successfully reconstituted in the laboratory the enzyme responsible for producing the blockbuster cholesterol-lowering drug lovastatin.

4 Nov 2009

Arrowhead Research updates its shareholders

Arrowhead Research Corporation’s (NASDAQ: ARWR) President and Chief Executive Officer today issued the following letter to the Company’s shareholders.

3 Nov 2009

Seaside Therapeutics commences STX107 Phase 1 clinical trial for Fragile X Syndrome

Seaside Therapeutics LLC today announced that the Company has initiated a Phase 1 clinical trial of STX107, a highly potent, selective mGluR5 antagonist, in development for the treatment of Fragile X Syndrome. The single ascending dose study is designed to evaluate the safety, tolerability and pharmacokinetics of STX107 in healthy volunteers. Fragile X Syndrome is the most common inherited form of mental impairment and the most common known cause of autism.

3 Nov 2009

Caliper Life Sciences to use SRU Biosystems’ label-free BIND technology for new functional assays

SRU Biosystems today announced that Caliper Life Sciences will use SRU Biosystems’ label-free BIND® technology to offer new functional assays as part of its Discovery Alliances and Services.

3 Nov 2009

Mechanical force switches T cell from disease-scanning to disease-fighting mode

The immune system's T cells have the unique responsibilities of being both jury and executioner. They examine other cells for signs of disease, including cancers or infections, and, if such evidence is found, rid them from the body. Precisely how T cells shift so swiftly from one role to another, however, has been a mystery.

3 Nov 2009

Hormone deficiency may be the cause for chronic diarrhoea

A common type of chronic diarrhoea may be caused by a hormone deficiency, according to new research published in the November issue of Clinical Gastroenterology and Hepatology.

3 Nov 2009

Avila Therapeutics presents preclinical study data of its AVL-181 HCV protease inhibitor

Avila Therapeutics™, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181. Avila showed that AVL-181 promoted complete viral clearance in vitro when used at clinically-relevant concentrations in combination with other HCV therapies.

2 Nov 2009

Nuevolution receives milestone payment from Merck

Nuevolution A/S today announced that it has received a milestone payment derived from its collaboration with Merck & Co. Inc., Whitehouse Station, NJ.

2 Nov 2009

FDA-approved drug PEG-ADA shows positive results in relieving major complication of priapism

Thousands of men are afflicted with an embarrassing and painful condition that triggers spontaneous, long-lasting erections. There are limited treatment options, but a solution could be on the way thanks to new research at The University of Texas Health Science Center at Houston.

31 Oct 2009

NeoStem completes acquisition of China Biopharmaceuticals Holdings

NeoStem, Inc., announced today that the Company has completed the acquisition of China Biopharmaceuticals Holdings, Inc., a leading Chinese pharmaceutical company.

30 Oct 2009

Clinical data on the validation set 'Alzheimer patients versus healthy controls' for AclarusDx presented

ExonHit Therapeutics yesterday presented clinical data on the validation set “Alzheimer patients versus healthy controls” for AclarusDx™ (formerly EHT Dx21), its blood-based diagnostic test for the detection of Alzheimer’s disease (AD), at the 2nd Conference of Clinical Trials on Alzheimer’s Disease (CTAD) in Las Vegas, USA.

30 Oct 2009

New state-of-the-art biotechnology center opened on the West Coast

As part of its strategy to discover and develop more biotechnology medicines, Eli Lilly and Company today officially opened a new state-of-the-art biotechnology center on the West Coast.

30 Oct 2009

Study: HSP inhibitor could stop tumor formation and extend survival

Like yoga for office drones, cells do have coping strategies for stress. Heat, lack of nutrients, oxygen radicals - all can wreak havoc on the delicate internal components of a cell, potentially damaging it beyond repair. Proteins called HSPs (heat shock proteins) allow cells to survive stress-induced damage. Scientists have long studied how HSPs work in order to harness their therapeutic potential.

30 Oct 2009

Genetic mutations may put individuals at increased risk for fungal infections

New research has identified two genetic mutations that may put individuals at increased risk for fungal infections. The research focused on patients with severe fungal infections (primarily of the genus Candida), but the findings may also have implications for patients who have more common mild infections.

29 Oct 2009

Molecule News and Research

Third quarter 2009 financial results announced by Synta Pharmaceuticals

Exelixis to present 13 abstracts of its development candidates at the 2009 AACR-NCI-EORTC Conference

Researchers to find better ways to manage chronic pain by treating neuroinflammation

Hydrogen peroxide may act as a signal for the active and resting phases of living things: Study

Scientists identify compounds that hold promise for treating parasitic infection

New molecular pathway for preventing potassium from being excreted normally through kidney identified

Lovastatin-synthesizing enzyme successfully reconstituted

Arrowhead Research updates its shareholders

Seaside Therapeutics commences STX107 Phase 1 clinical trial for Fragile X Syndrome

Caliper Life Sciences to use SRU Biosystems’ label-free BIND technology for new functional assays

Mechanical force switches T cell from disease-scanning to disease-fighting mode

Hormone deficiency may be the cause for chronic diarrhoea

Avila Therapeutics presents preclinical study data of its AVL-181 HCV protease inhibitor

Nuevolution receives milestone payment from Merck

FDA-approved drug PEG-ADA shows positive results in relieving major complication of priapism

NeoStem completes acquisition of China Biopharmaceuticals Holdings

Clinical data on the validation set 'Alzheimer patients versus healthy controls' for AclarusDx presented

New state-of-the-art biotechnology center opened on the West Coast

Study: HSP inhibitor could stop tumor formation and extend survival

Genetic mutations may put individuals at increased risk for fungal infections

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News